Comparative

Human disease

mucopolysaccharidosis type 6

MONDO:0009661

Mondo defines it as: “Mucopolysaccharidosis type 6 (MPS 6) is a lysosomal storage disease with progressive multisystem involvement, associated with a deficiency of arylsulfatase B (ASB) leading to the accumulation of dermatan sulfate.”

1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.

Animal diseases

By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.

OMIA group Name Found by Species The chain reached Score
666 Mucopolysaccharidosis VI Both routes 2 Target evidence 87.5

Human genes

Each human gene of these disease groups that Open Targets links to this disease.

Human gene Score Evidence
ARSB 0.87 1,233

Drugs tested for this disease

Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.

Drug Acts on Latest stage for this disease
Galsulfase None of these genes Phase 3
Somatropin None of these genes Phase 2/3
Antilymphocyte Immunoglobulin (Horse) None of these genes Phase 2
Busulfan None of these genes Phase 2
Cyclophosphamide Anhydrous None of these genes Phase 2
Odiparcil None of these genes Phase 2
Adalimumab None of these genes Phase 1/2
Vosoritide None of these genes Phase 1/2

The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.